

## Optum360 Coding for Coronavirus (COVID-19)

Below is an overview of and industry guidance for coding changes related to the 2019 novel coronavirus (COVID-19).

### ICD-10-CM Codes

The Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NCHS), the federal agency responsible for maintaining the International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Clinical Modification (ICD-10-CM) in the United States, implemented the following ICD-10-CM code effective April 1, 2020:

**U07.1** COVID-19

Six new ICD-10-CM codes were created for the capture of COVID-19 related encounters, effective January 1, 2021, through September 30, 2021.

**J12.82** Pneumonia due to coronavirus disease 2019

**M35.81** Multisystem inflammatory syndrome

**M35.89** Other specified systemic involvement of connective tissue

**Z11.52** Encounter for screening for COVID-19

**Z20.822** Contact with and (suspected) exposure to COVID-19

**Z86.16** Personal history of COVID-19

New guidelines specific to COVID-19 coding were added to the ICD-10-CM *Official Guidelines for Coding and Reporting* effective April 1, 2020. Since that time the full official guidelines have been updated twice, October 1, 2020, and January 1, 2021.

### ICD-10-PCS Codes

The Centers for Medicare and Medicaid Services (CMS) has added 12 new procedure codes to the International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), effective August 1, 2020. These codes describe the introduction or infusion of therapeutics, including remdesivir and convalescent plasma, current treatments used to manage COVID-19 patients. These codes do not affect MS-DRG assignment.

**XW013F5** Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5

**XW033E5** Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5

**XW033F5** Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5

**XW033G5** Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

**XW033H5** Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5

*Continued on next page*

<b>XW043E5</b>	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
<b>XW043F5</b>	Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
<b>XW043G5</b>	Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
<b>XW043H5</b>	Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
<b>XW0DXF5</b>	Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
<b>XW133Z5</b>	Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5
<b>XW143Z5</b>	Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5

CMS added 21 new ICD-10-PCS procedure codes, effective January 1, 2021. These codes describe the introduction or infusion of therapeutics, including monoclonal antibodies and vaccines, for COVID-19 treatment. These codes do not affect MS-DRG assignment.

<b>XW013H6</b>	Introduction of other new technology monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
<b>XW013K6</b>	Introduction of leronlimab monoclonal antibody into subcutaneous tissue, percutaneous approach, new technology group 6
<b>XW013S6</b>	Introduction of COVID-19 vaccine dose 1 into subcutaneous tissue, percutaneous approach, new technology group 6
<b>XW013T6</b>	Introduction of COVID-19 vaccine dose 2 into subcutaneous tissue, percutaneous approach, new technology group 6
<b>XW013U6</b>	Introduction of COVID-19 vaccine into subcutaneous tissue, percutaneous approach, new technology group 6
<b>XW023S6</b>	Introduction of COVID-19 vaccine dose 1 into muscle, percutaneous approach, new technology group 6
<b>XW023T6</b>	Introduction of COVID-19 vaccine dose 2 into muscle, percutaneous approach, new technology group 6
<b>XW023U6</b>	Introduction of COVID-19 vaccine into muscle, percutaneous approach, new technology group 6
<b>XW033E6</b>	Introduction of etesevimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
<b>XW033F6</b>	Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6

*Continued on next page*

- XW033G6** Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
- XW033H6** Introduction of other new technology monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6
- XW033L6** Introduction of CD24Fc immunomodulator into peripheral vein, percutaneous approach, new technology group 6
- XW043E6** Introduction of etesevimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
- XW043F6** Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6
- XW043G6** Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6
- XW043H6** Introduction of other new technology monoclonal antibody into central vein, percutaneous approach, new technology group 6
- XW043L6** Introduction of CD24Fc immunomodulator into central vein, percutaneous approach, new technology group 6
- XW0DXM6** Introduction of baricitinib into mouth and pharynx, external approach, new technology group 6
- XW0G7M6** Introduction of baricitinib into upper GI, via natural or artificial opening, new technology group 6
- XW0H7M6** Introduction of baricitinib into lower GI, via natural or artificial opening, new technology group 6

## HCPCS Level II Codes

Two new HCPCS Level II codes were created for coronavirus testing, effective April 1, 2020, for dates of service starting February 4, 2020.

- U0001** CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel  
*For tests developed only by the CDC (reporting allows CDC testing laboratories to test new patients and track new cases).*
- U0002** 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC  
*For laboratories performing non-CDC testing.*

Two new HCPCS Level II codes were created for coronavirus testing using *high throughput technologies*, effective April 14, 2020 (reportable for services provided on March 18, 2020, and forward).

- U0003** Infectious agent detection by nucleic acid (DNA or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R

**U0004** 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R

Two new HCPCS Level II codes were created for specimen collection, effective March 1, 2020.

**G2023** Specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source

**G2024** Specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) from an individual in a SNF or by a laboratory on behalf of a HHA, any specimen source

A new HCPCS Level II code was created for coronavirus specimen collection for hospital outpatient clinics, effective March 1, 2020.

**C9803** Hospital outpatient clinic visit specimen collection for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source

Modifier CS was revised and may be appended to COVID-19 related testing services provided on or after March 18, 2020, to indicate that the cost-sharing waiver is applied, and the Medicare patient should not be charged coinsurance or deductible.

**CS** Cost-sharing for specified COVID-19 testing-related services that result in an order for or administration of a COVID-19 test

Modifier CS was revised and may be appended to COVID-19 related testing services provided on or after July 1, 2020, to identify that the cost-sharing waiver is applied and the Medicare patient should not be charged coinsurance or deductible, for services furnished via telehealth in rural health clinics and federally qualified health centers.

**CS** Cost-sharing waived for specified COVID-19 testing-related services that result in an order for, or administration of, a COVID-19 test and/or used for cost-sharing waived preventive services furnished via telehealth in Rural Health Clinics and Federally Qualified Health Centers during the COVID-19 public health emergency

Two new HCPCS Level II codes were created for investigational monoclonal antibody therapy for specific patients who test positive for COVID-19, effective November 10, 2020.

**M0239** Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring

**Q0239** Injection, bamlanivimab-xxxx, 700 mg

Two new HCPCS Level II codes were created for investigational monoclonal antibody therapy for specific patients who test positive for COVID-19, effective November 21, 2020.

**M0243** Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring

**Q0243** Injection, casirivimab and imdevimab, 2400 mg

Two new HCPCS Level II codes were created for investigational monoclonal antibody therapy for specific patients who test positive for COVID-19, effective February 9, 2021.

- M0245** Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
- Q0245** Injection, bamlanivimab and etesevimab, 2100 mg

Two new HCPCS Level II codes were created for investigational monoclonal antibody therapy for specific patients who test positive for COVID-19, effective May 6, 2021.

- M0244** Intravenous infusion, casirivimab and imdevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency
- M0246** Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency

Two HCPCS Level II codes were **deleted**, effective April 17, 2021 (originally newly effective on November 10, 2020).

- M0239** Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
- Q0239** Injection, bamlanivimab-xxxx, 700 mg

One new HCPCS Level II code was created for reporting COVID-19 vaccines, effective June 8, 2021, and three new codes were created for investigational monoclonal antibody therapy for specific patients who test positive for COVID-19, effective May 26, 2021.

- M0201** COVID-19 vaccine administration inside a patient's home; reported only once per individual home, per date of service, when only COVID-19 vaccine administration is performed at the patient's home
- M0247** Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
- M0248** Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency
- Q0247** Injection, sotrovimab, 500 mg

Three new codes were created for investigational monoclonal antibody therapy for specific patients who are hospitalized, effective June 24, 2021.

- M0249** Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose
- M0250** Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose

- Q0249** Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg

Three new codes were created for investigational monoclonal antibody therapy for specific patients who are hospitalized, effective July 30, 2021.

- M0240** Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses
- M0241** Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses
- Q0240** Injection, casirivimab and imdevimab, 600 mg

### CPT® Codes

One new CPT code was created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, effective March 13, 2020.

- 87635** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique

Two new CPT codes were created and one revised for reporting COVID-19 antibody testing, effective April 10, 2020.

- 86318** Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip);
- #86328** Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
- Code #86328 is a resequenced code that follows code 86318.*
- 86769** Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])

A new proprietary laboratory analysis CPT code was created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, effective May 20, 2020.

- 0202U** Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected

A new CPT code and two PLA CPT codes were created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, effective June 25, 2020.

- 87426** Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])

- 0223U** Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected
- 0224U** Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed

Two new CPT codes and one PLA CPT code were created for reporting COVID-19 neutralizing antibody testing, and one additional PLA CPT code was created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, effective August 10, 2020.

- #86408** Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen
- #86409** Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer  
*Codes #86408 and #86409 are resequenced codes that follow code 86352.*
- 0225U** Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
- 0226U** Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum

Two new CPT codes were created, one for reporting COVID-19 antibody testing, and one for reporting additional supplies and clinical staff time required during a public health emergency (PHE), effective September 8, 2020.

- #86413** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative  
*Code #86413 is a resequenced code that follows resequenced code 86409.*
- 99072** Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other nonfacility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease

Three new CPT codes were created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, two additional PLA CPT codes were created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, and one CPT code was revised, effective October 6, 2020.

- 87636** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
- 87637** Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
- #87811** Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])



- 0240U** Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected
- 0241U** Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected
- 87426** Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])

One new CPT code was created for reporting coronavirus 2 (SARS-CoV-2) COVID-19 testing, and six new codes for reporting COVID-19 vaccines, effective November 10, 2020.

- 87428** Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
- #0001A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
- #0002A** second dose
- #0011A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
- #0012A** second dose
- #91300** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
- #91301** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use

Three new CPT codes were created for reporting COVID-19 vaccines, effective December 17, 2020.

- #0021A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free,  $5 \times 10^{10}$  viral particles/0.5mL dosage; first dose
- #0022A** second dose
- #91302** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free,  $5 \times 10^{10}$  viral particles/0.5mL dosage, for intramuscular use



Two new CPT codes were created for reporting COVID-19 vaccines, effective January 19, 2021.

- #0031A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free,  $5 \times 10^{10}$  viral particles/0.5mL dosage, single dose
- #91303** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free,  $5 \times 10^{10}$  viral particles/0.5mL dosage, for intramuscular use

Three new CPT codes were created for reporting COVID-19 vaccines, effective May 4, 2021.

- #0041A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose
- #0042A** second dose
- #91304** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use

A new CPT code was created for reporting a third dose of the Pfizer-BioNTech COVID-19 vaccine, effective August 12, 2021.

- #0003A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose

A new CPT code was created for reporting a third dose of the Moderna COVID-19 Vaccine, effective August 12, 2021.

- #0013A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose

Eight new CPT codes were created for reporting COVID-19 vaccines, effective September 3, 2021.

- #0004A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose
- #0051A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose
- #0052A** second dose
- #0053A** third dose
- #0054A** booster dose
- #0064A** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose

*Continued on next page*

**#91305** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use

**#91306** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use

*For a listing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine and administration codes, along with the manufacturer, NDC, and dosing intervals, refer to the table at the end of this document.*

*A HCPCS code and CPT code should not be reported together for COVID-19 testing, vaccines, or monoclonal antibody therapy. Providers should contact third-party payer(s) for their guidance on whether to report a CPT or a HCPCS code, as well as for retroactive billing and reimbursement guidelines.*

## DRG Coding

Assignment of new ICD-10-CM diagnosis code U07.1 COVID-19, is as follows:

Diagnosis Code	Description	CC	MDC	MS-DRG
U07.1	COVID-19	MCC	04	177, 178, 179
			15	791, 793
			25	974, 975, 976

When a patient is admitted with a diagnosis of COVID-19 and this diagnosis meets the definition of principal or first-listed diagnosis, code U07.1 COVID-19, should be sequenced first, followed by the appropriate codes for associated manifestations, except as otherwise guided by the classification and guidelines.

Code U07.1 is assigned to MDC 04 Diseases & Disorders of the Respiratory System. It is included in the principal diagnosis list for MS-DRGs 177, 178, and 179 Respiratory Infections and Inflammations. Any manifestations would be coded as secondary diagnoses and would act as CC/MCC if they apply.

**DRG 177** Respiratory Infections and Inflammations with MCC

**DRG 178** Respiratory Infections and Inflammations with CC

**DRG 179** Respiratory Infections and Inflammations without CC/MCC

If the patient is placed on a ventilator, MS-DRGs 207–208 would be assigned, depending on the duration of the ventilator support.

**DRG 207** Respiratory System Diagnosis with Ventilator Support >96 Hours

**DRG 208** Respiratory System Diagnosis with Ventilator Support ≤96 Hours

In the case of newborns diagnosed during the birth episode, according to chapter-specific guidelines, a code from category Z38 is assigned as the principal diagnosis and code U07.1 is assigned as a secondary diagnosis. Newborns are categorized in MDC 15 Newborns & Other Neonates with Conditions Originating in Perinatal Period.

Code U07.1 is listed in the secondary diagnosis major problems list for MS-DRGs 791 Prematurity with Major Problems, and 793 Full Term Neonate with Major Problems.

**DRG 791** Prematurity with Major Problems

**DRG 793** Full Term Neonate with Major Problems

According to the ICD-10-CM COVID-19 guidelines, during pregnancy, childbirth, or the puerperium, a patient admitted (or presenting for a health care encounter) because of COVID-19 should receive a principal diagnosis code of O98.5- Other viral diseases complicating pregnancy, childbirth, and the puerperium, followed by code U07.1 COVID-19, and the appropriate codes for associated manifestation(s). Codes from chapter 15 always take sequencing priority. The MS-DRG

that will be assigned in MDC 14 Pregnancy, Childbirth, and Puerperium depends on whether the episode of care was antepartum, with or without operating room procedures, postpartum, or for delivery, the type of delivery (vaginal vs. cesarean section), if the patient had a sterilization procedure, and the presence or absence of MCC/CC complicating conditions.

If a patient is admitted with a principal diagnosis of COVID and has underlying HIV, the case is assigned to MDC 25 Human Immunodeficiency Virus Infections, in MS-DRGs 974, 975, and 976. If the patient is admitted with an HIV principal diagnosis with a secondary diagnosis of COVID, the COVID code U07.1 acts as a major related condition to the HIV instead of an MCC, and the case is assigned to MDC 25 Human Immunodeficiency Virus Infections, in MS-DRGs 974, 975, and 976.

**DRG 974** HIV with Major Related Condition with MCC

**DRG 975** HIV with Major Related Condition with CC

**DRG 976** HIV with Major Related Condition without CC/MCC

**Other Resources:** Visit [optum360coding.com/covid-19-coding](https://optum360coding.com/covid-19-coding).

### Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine and Administration Codes

The following table provides a link between each individual Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine code and its corresponding vaccine administration code, along with the vaccine manufacturer name, vaccine name, National Drug Code (NDC) Labeler Product ID number(s), the recommended interval between vaccine doses, and the Emergency Use Authorization (EUA) or Federal Drug Administration (FDA) approval dates (when received). These resequenced codes are located in the Medicine section. Additional instructional notes can be found with the codes in the appropriate code ranges or at <https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes>.

Vaccine Code	Long Descriptor	Administration Code(s)	Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (vial)	Dosing Interval	Location in Optum360 coding products	EUA or FDA Approval Date
#•91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	#•0001A (1st dose) #•0002A (2nd dose) #•0003A (3rd dose) #•0004A (booster dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine, Comirnaty	59267-1000-1 59267-1000-01	1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance	[91300] - Before code 90476	12/11/2020 (EUA); 8/12/2021 (0003A, EUA); FDA approval 8/23/2021; 9/3/2021 (EUA, booster dose)
#•91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	#•0051A (1st dose) #•0052A (2nd dose) #•0053A (3rd dose) #•0054A (booster dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1025-1 59267-1025-01	1st to 2nd dose: 21 days 2nd to 3rd dose: 28 or more days Booster: See FDA/CDC Guidance	[91305] - Following resequenced code 91300	9/3/2021 (EUA)
#•91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	#•0011A (1st dose) #•0012A (2nd dose) #•0013A (3rd dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	1st to 2nd dose: 28 days 2nd to 3rd dose: 28 or more days	[91301] - Before code 90476	12/18/2020 (EUA) (0013A)

#•91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	#•0064A (booster dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	See FDA/CDC Guidance	[91306] - Following resequenced code 91301	9/3/2021 (EUA)
#•91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>&gt;10</sup> viral particles/0.5mL dosage, for intramuscular use	#•0021A (1st dose) #•0022A (2nd dose)	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 days	[91302] - Before code 90476	Not yet received
#•91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>&gt;10</sup> viral particles/0.5mL dosage, for intramuscular use	#•0031A (single dose)	Janssen	Janssen COVID-19 Vaccine	59676-580-05 59676-0580-05	N/A	[91303] - Before code 90476	01/19/2021 (EUA); 02/27/2021 (FDA)
#•91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use	#•0041A (1st dose) #•0042A (2nd dose)	Novavax, Inc	Novavax COVID-19 Vaccine	80631-100-01 80631-1000-01	21 Days	[91304] - Before code 90476	05/04/2021 (EUA)

**Notes:**

COVID-19 vaccine drug codes [91300, 91301, 91302, 91303, 91304, 91305, 91306] are exempt from reporting with modifier 51.

COVID-19 vaccine administration codes [0001A-0004A, 0011A-0013A, 0021A-0022A, 0031A, 0041A-0042A, 0051A-0054A, 0064A] should be reported with vaccine codes [91300, 91301, 91302, 91303, 91304, 91305, 91306] [ITAL]only[END ITAL]. All other vaccines should be reported with [90460-90461], 90476-90749. COVID-19 vaccine administration codes should not be reported with other immunization administration codes unless an additional vaccine/toxoid is administered during the same visit.